- Home
- ADRX vs ZYME Comparison
ADRX vs ZYME Comparison
Compare ADRX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADRX | ZYME |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ADRX | ZYME |
|---|---|---|
| Price | $14.58 | $26.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $34.25 | ★ $43.23 |
| AVG Volume (30 Days) | 396.7K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 1.08 |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $89.41 | $216.20 |
| Revenue Next Year | $510.33 | $7.81 |
| P/E Ratio | ★ N/A | $24.65 |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $12.50 | $21.52 |
| 52 Week High | $19.57 | $31.97 |
Technical Indicators
Market Signals| Indicator | ADRX | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 41.75 |
| Support Level | $12.50 | $25.21 |
| Resistance Level | $18.94 | $27.40 |
| Average True Range (ATR) | 1.59 | 1.41 |
| MACD | -0.16 | -0.33 |
| Stochastic Oscillator | 30.24 | 5.69 |
Price Performance
Historical ComparisonAbout ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.